Sentence: This 40-week open-label extension of the 12-week double-blind Triple Therapy With Olmesartan Medoxomil , Amlodipine , and Hydrochlorothiazide in Hypertensive Patients Study ( TRINITY ) evaluated the efficacy and safety of triple-combination treatments with olmesartan medoxomil , amlodipine besylate , and hydrochlorothiazide ( OM/AML/HCTZ ) in 2112 participants with moderate to severe hypertension .
Drug combination annotation:
[{'class': 'POS', 'spans': ['Olmesartan', 'Amlodipine', 'Hydrochlorothiazide'], 'is_context_needed': True}]